CV Sciences Inc (CVSI)

[Wolf-man jack]

WQLF SAYS; Follow up to the WQKIMON Question about the PAST EXPERIENCES of the CEO of CV Sciences Joseph Dowling. Here is a startup company he was involved with when it was formed in 2012. It is still a growing and striving corporation that is a Global Business organization thanks to his leadership and experience in making startups successful as he has done with CV Sciences.

“Digitech Solutions, Inc.: Digitech Solutions, Inc. is an electronics company located in Los Angeles, California. The company focuses on providing services and solutions tailored for designers, emphasizing creativity, style, and ideas. They offer home automation services, which include advanced systems to enhance the functionality and convenience of smart homes. Their commitment to designers is reflected in their mission to support and empower creative professionals.
The company can be reached through their email at info @Tamulonis. They are active on social media platforms such as Facebook, Twitter, and Instagram, where they share updates and engage with their community.
Reviews and ratings for Digitech Solutions, Inc. are not provided in the available context, but the company's focus on designer-centric services and home automation suggests a strong emphasis on innovation and customer satisfaction. If you are a designer or interested in home automation, Digitech Solutions, Inc. may be a valuable resource for your needs.“

http://digitechsolutions.com/

Who we are;

“Built on 12 years of reputation and experience, Digitech Solutions can offer telecommunication solutions to any type of organisation.
Digitech can offer you and your company, services including Special Rate Service Numbers, Premium Rate Service Numbers, Carrier Pre-Select, Tailor made Call Plans and now we are able to bring to you SMS services.
We can offer you ready-made SMS products that enable you to generate revenue immediately. In addition to this we are constantly releasing new products to our SMS range every week and many of these are exclusive to Digitech Solutions.
The future of Your Call Centre Options are Just a Phone Call Away.”

Digitech Solutions Global Limited, The Business Centre, 1 Finway Luton LU1 1TR

http://digitechsolutions.com/aboutUs.html

NEXT ⬆️ UP

“ About MediVas

Using its proprietary family of biodegradable and biocompatible polymers, MediVas has developed unique platforms for the delivery of biologics. MediVas is utilizing its novel polymer technology in collaboration with some of the world's largest pharmaceutical companies, as well as on its own internal product development efforts, to create groundbreaking medical advancements.

By combining therapeutic proteins and other biologics with a MediVas polymer, delivery routes that were previously unattainable, such as oral, intranasal, inhaled or subcutaneous injection, can now be achieved. With these routes of delivery then available, MediVas' delivery system can make the administration of the biologic more convenient, more efficacious and safer, leading to higher patient compliance and overall better health.”

https://www.bionity.com/en/companies/22706/medivas-llc.html

DSM obtains exclusive world-wide license for MediVas' drug delivery technology

13-Mar-2009 - Netherlands
Royal DSM N.V announced that DSM Biomedical obtained an exclusive world-wide license for a unique drug & biologics delivery system developed by MediVas LLC. Integrated into DSM's Trancerta® drug delivery platform, this will open up a broad range of opportunities for next generation drug delivery. DSM's activities in this field are an illustration of the way DSM is leveraging its competences in Materials Sciences into Life Sciences applications.

MediVas' technology for the delivery of biologics and drugs is based on a next generation set of polymers exclusively licensed from Cornell University. Generated from research both at Cornell and at MediVas, the company has an IP portfolio containing over 60 issued or pending patents. The polymers are biodegradable, biocompatible and bioabsorbable. Furthermore they are non-inflammatory and allow greater control over the rate and duration of release of their therapeutic payload.

The technology can be used with a diverse group of drug candidates, from small molecule drugs to large molecules like proteins, peptides and nucleic acids, thus expanding the possible application areas of DSM's Trancerta® platform. The license DSM obtained applies for the development of drug delivery systems aimed at treating ophthalmic, (cardio)vascular, musculoskeletal diseases and at providing general pain relief.

"Through this deal we bring in the first fully developed biodegradable polymer into DSM's Biomedical portfolio, which significantly enhances our materials competences. This will help us realize our ambition to build a portfolio of drug delivery technologies tailored at the specific needs of the health industry. MediVas' technology is already proven in two clinical studies which should allow us to accelerate the commercialization of our drug delivery technologies in partnerships with Pharma, Biotech and Medical Device companies," said Steve Hartig, President of DSM Biomedical.